A World Allergy Organization International Survey on Diagnostic Procedures and Therapies in Drug Allergy/Hypersensitivity

Table 3 Commercially Available In Vitro-Specific IgE Tests

	Europe, n (%)	Asia Pacific, n (%)	North America, n (%)	Latin America, n (%)	Africa Middle East, n (%)	Region Not Specified, n (%)	Total (n = 62), n (%)
CAP-FEIA	25 (40.3)	9 (14.5)	6 (9.7)	3 (4.8)	4 (6.5)	3 (4.8)	50 (80.6)
RAST	18 (29.0)	3 (4.8)	4 (6.5)	3 (4.8)	4 (6.5)	3 (4.8)	35 (56.5)
CAST-ELISA	10 (16.1)	1 (1.6)	0 (0.0)	2 (3.2)	2 (3.2)	1 (1.6)	16 (25.8)
FLOW-CAST	11 (17.7)	1 (1.6)	1 (1.6)	0 (0.0)	0 (0.0)	2 (3.2)	15 (24.2)
FLOW-2-CAST	8 (11.1)	0 (0.0)	1 (1.6)	0 (0.0)	2 (3.2)	2 (3.2)	9 (14.5)

Percentage represents percentage of all 72 respondents who answered this question.
CAP-FEIA, immunoCAP fluorescent enzyme immunoassay; CAST-ELISA, cellular allergen stimulation test enzyme-linked immunosorbent assay; FLOW-CAST, flow cytometry cellular allergen stimulation test; FLOW-2-CAST: flow cytometry-2-cellular allergen stimulation test; RAST, radio allergosorbent test.

ISSN: 1939-4551